Metal-analysis of the implantable cardioverter defibrillator secondary prevention trials

S. J. Connolly, A. P. Hallstrom, R. Cappato, E. B. Schron, K. H. Kuck, D. P. Zipes, H. L. Greene, S. Boczor, M. Domanski, D. Follmann, M. Gent, R. S. Roberts

Research output: Contribution to journalArticle

785 Citations (Scopus)

Abstract

Aims: Three randomized trials of implantable cardioverter defibrillator (ICD) therapy vs medical treatment for the prevention of death in survivors of ventricular fibrillation or sustained ventricular tachycardia have been reported with what might appear to be different results. The present analysis was performed to obtain the most precise estimate of the efficacy of the ICD, compared to amiodarone, for prolonging survival in patients with malignant ventricular arrhythmia. Methods and Results: Individual patient data from the Antiarrhythmics vs Implantable Defibrillator (AVID) study, the Cardiac Arrest Study Hamburg (CASH) and the Canadian Implantable Defibrillator Study (CIDS) were merged into a master database according to a pre-specified protocol. Proportional hazard modelling of individual patient data was used to estimate hazard ratios and to investigate subgroup interactions. Fixed effect meta-analysis techniques were also used to evaluate treatment effects and to assess heterogeneity across studies. The classic fixed effects meta-analysis showed that the estimates of ICD benefit from the three studies were consistent with each other (P heterogeneity=0.306). It also showed a significant reduction in death from any cause with the ICD; with a summary hazard ratio (ICD:amiodarone) of 0.72 (95% confidence interval 0.60, 0.87; P=0.0006). For the outcome of arrhythmic death, the hazard ratio was 0.50 (95% confidence interval 0.37, 0.67; P

Original languageEnglish (US)
Pages (from-to)2071-2078
Number of pages8
JournalEuropean Heart Journal
Volume21
Issue number24
DOIs
StatePublished - 2000
Externally publishedYes

Fingerprint

Implantable Defibrillators
Secondary Prevention
Metals
Amiodarone
Meta-Analysis
Confidence Intervals
Ventricular Fibrillation
Ventricular Tachycardia
Heart Arrest
Survivors
Cardiac Arrhythmias
Cause of Death
Therapeutics
Databases
Survival

Keywords

  • Amiodarone
  • Cardiac arrest
  • Implantable cardioverter defibrillator
  • Meta-analysis
  • Ventricular tachycardia

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Connolly, S. J., Hallstrom, A. P., Cappato, R., Schron, E. B., Kuck, K. H., Zipes, D. P., ... Roberts, R. S. (2000). Metal-analysis of the implantable cardioverter defibrillator secondary prevention trials. European Heart Journal, 21(24), 2071-2078. https://doi.org/10.1053/euhj.2000.2476

Metal-analysis of the implantable cardioverter defibrillator secondary prevention trials. / Connolly, S. J.; Hallstrom, A. P.; Cappato, R.; Schron, E. B.; Kuck, K. H.; Zipes, D. P.; Greene, H. L.; Boczor, S.; Domanski, M.; Follmann, D.; Gent, M.; Roberts, R. S.

In: European Heart Journal, Vol. 21, No. 24, 2000, p. 2071-2078.

Research output: Contribution to journalArticle

Connolly, SJ, Hallstrom, AP, Cappato, R, Schron, EB, Kuck, KH, Zipes, DP, Greene, HL, Boczor, S, Domanski, M, Follmann, D, Gent, M & Roberts, RS 2000, 'Metal-analysis of the implantable cardioverter defibrillator secondary prevention trials', European Heart Journal, vol. 21, no. 24, pp. 2071-2078. https://doi.org/10.1053/euhj.2000.2476
Connolly SJ, Hallstrom AP, Cappato R, Schron EB, Kuck KH, Zipes DP et al. Metal-analysis of the implantable cardioverter defibrillator secondary prevention trials. European Heart Journal. 2000;21(24):2071-2078. https://doi.org/10.1053/euhj.2000.2476
Connolly, S. J. ; Hallstrom, A. P. ; Cappato, R. ; Schron, E. B. ; Kuck, K. H. ; Zipes, D. P. ; Greene, H. L. ; Boczor, S. ; Domanski, M. ; Follmann, D. ; Gent, M. ; Roberts, R. S. / Metal-analysis of the implantable cardioverter defibrillator secondary prevention trials. In: European Heart Journal. 2000 ; Vol. 21, No. 24. pp. 2071-2078.
@article{97d149e3e1ab4f1981f249d77ae71eb0,
title = "Metal-analysis of the implantable cardioverter defibrillator secondary prevention trials",
abstract = "Aims: Three randomized trials of implantable cardioverter defibrillator (ICD) therapy vs medical treatment for the prevention of death in survivors of ventricular fibrillation or sustained ventricular tachycardia have been reported with what might appear to be different results. The present analysis was performed to obtain the most precise estimate of the efficacy of the ICD, compared to amiodarone, for prolonging survival in patients with malignant ventricular arrhythmia. Methods and Results: Individual patient data from the Antiarrhythmics vs Implantable Defibrillator (AVID) study, the Cardiac Arrest Study Hamburg (CASH) and the Canadian Implantable Defibrillator Study (CIDS) were merged into a master database according to a pre-specified protocol. Proportional hazard modelling of individual patient data was used to estimate hazard ratios and to investigate subgroup interactions. Fixed effect meta-analysis techniques were also used to evaluate treatment effects and to assess heterogeneity across studies. The classic fixed effects meta-analysis showed that the estimates of ICD benefit from the three studies were consistent with each other (P heterogeneity=0.306). It also showed a significant reduction in death from any cause with the ICD; with a summary hazard ratio (ICD:amiodarone) of 0.72 (95{\%} confidence interval 0.60, 0.87; P=0.0006). For the outcome of arrhythmic death, the hazard ratio was 0.50 (95{\%} confidence interval 0.37, 0.67; P",
keywords = "Amiodarone, Cardiac arrest, Implantable cardioverter defibrillator, Meta-analysis, Ventricular tachycardia",
author = "Connolly, {S. J.} and Hallstrom, {A. P.} and R. Cappato and Schron, {E. B.} and Kuck, {K. H.} and Zipes, {D. P.} and Greene, {H. L.} and S. Boczor and M. Domanski and D. Follmann and M. Gent and Roberts, {R. S.}",
year = "2000",
doi = "10.1053/euhj.2000.2476",
language = "English (US)",
volume = "21",
pages = "2071--2078",
journal = "European Heart Journal",
issn = "0195-668X",
publisher = "Oxford University Press",
number = "24",

}

TY - JOUR

T1 - Metal-analysis of the implantable cardioverter defibrillator secondary prevention trials

AU - Connolly, S. J.

AU - Hallstrom, A. P.

AU - Cappato, R.

AU - Schron, E. B.

AU - Kuck, K. H.

AU - Zipes, D. P.

AU - Greene, H. L.

AU - Boczor, S.

AU - Domanski, M.

AU - Follmann, D.

AU - Gent, M.

AU - Roberts, R. S.

PY - 2000

Y1 - 2000

N2 - Aims: Three randomized trials of implantable cardioverter defibrillator (ICD) therapy vs medical treatment for the prevention of death in survivors of ventricular fibrillation or sustained ventricular tachycardia have been reported with what might appear to be different results. The present analysis was performed to obtain the most precise estimate of the efficacy of the ICD, compared to amiodarone, for prolonging survival in patients with malignant ventricular arrhythmia. Methods and Results: Individual patient data from the Antiarrhythmics vs Implantable Defibrillator (AVID) study, the Cardiac Arrest Study Hamburg (CASH) and the Canadian Implantable Defibrillator Study (CIDS) were merged into a master database according to a pre-specified protocol. Proportional hazard modelling of individual patient data was used to estimate hazard ratios and to investigate subgroup interactions. Fixed effect meta-analysis techniques were also used to evaluate treatment effects and to assess heterogeneity across studies. The classic fixed effects meta-analysis showed that the estimates of ICD benefit from the three studies were consistent with each other (P heterogeneity=0.306). It also showed a significant reduction in death from any cause with the ICD; with a summary hazard ratio (ICD:amiodarone) of 0.72 (95% confidence interval 0.60, 0.87; P=0.0006). For the outcome of arrhythmic death, the hazard ratio was 0.50 (95% confidence interval 0.37, 0.67; P

AB - Aims: Three randomized trials of implantable cardioverter defibrillator (ICD) therapy vs medical treatment for the prevention of death in survivors of ventricular fibrillation or sustained ventricular tachycardia have been reported with what might appear to be different results. The present analysis was performed to obtain the most precise estimate of the efficacy of the ICD, compared to amiodarone, for prolonging survival in patients with malignant ventricular arrhythmia. Methods and Results: Individual patient data from the Antiarrhythmics vs Implantable Defibrillator (AVID) study, the Cardiac Arrest Study Hamburg (CASH) and the Canadian Implantable Defibrillator Study (CIDS) were merged into a master database according to a pre-specified protocol. Proportional hazard modelling of individual patient data was used to estimate hazard ratios and to investigate subgroup interactions. Fixed effect meta-analysis techniques were also used to evaluate treatment effects and to assess heterogeneity across studies. The classic fixed effects meta-analysis showed that the estimates of ICD benefit from the three studies were consistent with each other (P heterogeneity=0.306). It also showed a significant reduction in death from any cause with the ICD; with a summary hazard ratio (ICD:amiodarone) of 0.72 (95% confidence interval 0.60, 0.87; P=0.0006). For the outcome of arrhythmic death, the hazard ratio was 0.50 (95% confidence interval 0.37, 0.67; P

KW - Amiodarone

KW - Cardiac arrest

KW - Implantable cardioverter defibrillator

KW - Meta-analysis

KW - Ventricular tachycardia

UR - http://www.scopus.com/inward/record.url?scp=17744375757&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17744375757&partnerID=8YFLogxK

U2 - 10.1053/euhj.2000.2476

DO - 10.1053/euhj.2000.2476

M3 - Article

C2 - 11102258

AN - SCOPUS:17744375757

VL - 21

SP - 2071

EP - 2078

JO - European Heart Journal

JF - European Heart Journal

SN - 0195-668X

IS - 24

ER -